Whalesbook
Stock Soars to 52-Week Peak
Apollo Hospitals Enterprise Ltd. shares climbed to a 52-week peak of Rs 8,388. This surge followed a significant 36% year-over-year increase in consolidated net profit, reaching Rs 529 crore for the fiscal fourth quarter ending March 2026. This strong performance contributed to a more than 4% gain in the stock over the three trading sessions leading up to the announcement. The company's revenue from operations also showed robust growth, rising 18.1% to Rs 6,605.5 crore compared to the previous year.
Financial Highlights of Q4
Healthy growth across all business segments fueled the strong Q4 results. The healthcare services division reported a 17.25% revenue increase, amounting to Rs 3,333.7 crore. Apollo Health and Lifestyle segments saw a notable 24.2% revenue rise to Rs 489.5 crore, while Apollo HealthCo's revenue grew by 20% to Rs 2,848.2 crore. For the full fiscal year 2026, consolidated net profit increased by 34% to Rs 1,942 crore, with revenue up 16% to Rs 25,229 crore. The company's EBITDA also saw a substantial 31% year-over-year increase in the quarter, reaching Rs 1,011 crore.
Strategic Moves: Divestment and Expansion
A significant strategic move was the announced sale of its fertility and maternity businesses to Cloudnine Hospitals for approximately Rs 1,550 crore. Apollo Hospitals will retain a minority stake in the combined entity. The proceeds from this sale are intended for further expansion, especially in diagnostics and other digital platforms. The company aims to add about 1,500 beds to its current base of over 10,900 beds within the next 12 to 18 months. Mid-teen revenue growth is projected for FY27. Additionally, the company is pursuing a composite scheme of arrangement to demerge specific units and consolidate pharmacy distribution into Apollo Healthtech Limited, aiming to boost digital health growth and operational efficiencies.
Analyst Views and Market Standing
Brokerage firms reacted positively to the financial results. Macquarie Group observed that the quarterly performance surpassed estimates for revenue, EBITDA, and adjusted PAT, noting an EBITDA margin of 15.3%. Motilal Oswal Financial Services highlighted strong EBITDA growth and margin expansion within Apollo HealthCo. The overall analyst sentiment is largely positive, with 28 buy recommendations, one hold, and one sell. The average analyst target price is around Rs 8,801.97, suggesting an approximate 8.41% upside potential from the recent closing price.
Valuation Snapshot
Apollo Hospitals's current Price-to-Earnings (P/E) ratio is approximately 63.40 as of May 20, 2026, slightly above the industry P/E of 62.02. While the trailing P/E of 61.71 as of March 5, 2026, indicates a premium valuation, the forward P/E of 46.36 suggests analysts expect earnings growth. The company's P/E ratio has fluctuated, peaking at 206.8x in March 2021 and reaching a 5-year low of 57.3x in March 2022. For comparison, competitors like Kovai Medical Center and Hospital Limited have a P/E ratio of 24.9x. However, Macquarie maintains a 'Sell' rating with a target price of Rs 5,700, citing concerns about slower organic growth in healthcare services and challenges in hospital network expansion.
Regulatory and Corporate Developments
The company is implementing several structural changes. A composite scheme of arrangement, approved by the National Company Law Tribunal, will consolidate its pharmacy distribution and digital health businesses. Furthermore, Apollo Hospitals North Limited is set to merge into Apollo Hospitals Enterprise Limited, pending regulatory approvals. The planned demerger of pharmacy and digital health businesses could lead to a listing by Q4 FY27. CRISIL has maintained an 'AA+' rating for Apollo Hospitals's long-term bank facilities with a 'Positive' outlook, underscoring its dominant market position and strong financial profile.
Future Prospects and Dividends
Apollo Hospitals forecasts mid-teen revenue growth for FY27. The board has recommended a final dividend of Rs 10 per equity share for FY26, subject to shareholder approval at the Annual General Meeting on August 25, 2026. The company also reported a 34% increase in consolidated net profit for the full fiscal year 2026. Analysts are optimistic about accelerated growth, predicting 19% annualised revenue growth through 2027, potentially matching industry growth rates of 21%. The consensus 12-month target price from analysts ranges from Rs 7,800 to Rs 8,500, indicating a 'Buy' recommendation, contingent on stable macro conditions and consistent delivery on earnings.